PMC:7170368 / 170-487 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"20","span":{"begin":116,"end":124},"obj":"Species"},{"id":"24","span":{"begin":75,"end":96},"obj":"Disease"},{"id":"25","span":{"begin":106,"end":114},"obj":"Disease"}],"attributes":[{"id":"A20","pred":"tao:has_database_id","subj":"20","obj":"Tax:9606"},{"id":"A24","pred":"tao:has_database_id","subj":"24","obj":"MESH:D018352"},{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T2","span":{"begin":23,"end":47},"obj":"Body_part"},{"id":"T3","span":{"begin":49,"end":52},"obj":"Body_part"},{"id":"T4","span":{"begin":138,"end":141},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"},{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"},{"id":"A4","pred":"uberon_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"}],"text":"The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T3","span":{"begin":87,"end":96},"obj":"Disease"},{"id":"T4","span":{"begin":106,"end":114},"obj":"Disease"}],"attributes":[{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":54,"end":57},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T3","span":{"begin":29,"end":40},"obj":"Chemical"},{"id":"T4","span":{"begin":49,"end":52},"obj":"Chemical"},{"id":"T5","span":{"begin":138,"end":141},"obj":"Chemical"},{"id":"T6","span":{"begin":142,"end":152},"obj":"Chemical"},{"id":"T7","span":{"begin":162,"end":202},"obj":"Chemical"},{"id":"T8","span":{"begin":162,"end":173},"obj":"Chemical"},{"id":"T9","span":{"begin":185,"end":202},"obj":"Chemical"},{"id":"T10","span":{"begin":192,"end":202},"obj":"Chemical"},{"id":"T11","span":{"begin":204,"end":209},"obj":"Chemical"},{"id":"T12","span":{"begin":215,"end":229},"obj":"Chemical"},{"id":"T15","span":{"begin":215,"end":226},"obj":"Chemical"},{"id":"T16","span":{"begin":227,"end":229},"obj":"Chemical"}],"attributes":[{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_63620"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_63620"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_23924"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_2719"},{"id":"A13","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_48432"},{"id":"A14","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_58506"},{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"}],"text":"The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown."}

{"project":"LitCovid-sentences","denotations":[{"id":"T7","span":{"begin":0,"end":317},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown."}